Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality? : A critical question that we are only just beginning to answer - 18/06/18
Doi : 10.1016/j.jaad.2018.03.046
Joel M. Gelfand, MD, MSCE ⁎ 
Departments of Dermatology and Epidemiology, the Dermatology Clinical Studies Unit, and Psoriasis and Phototherapy Treatment Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
∗Correspondence to: Joel M. Gelfand, MD, MSCE, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Blvd, 7th Fl, South Tower Office no. 730, Philadelphia, PA 19104.University of Pennsylvania Perelman School of Medicine3400 Civic Center Blvd7th Fl, South Tower Office no. 730PhiladelphiaPA19104
Key words : biologic, cardiovascular, mortality, myocardial infarction, psoriasis, stroke, TNF inhibitor
Le texte complet de cet article est disponible en PDF.
| Funding sources: Supported by the National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases K24-AR064310. |
|
| Conflicts of interest: Dr Gelfand served is a consultant for BMS, Boehringer Ingelheim, GSK, Janssen Biologics, Menlo Therapeutics, Novartis Corp, Regeneron, Dr Reddy's Labs, UCB (DSMB), Sanofi, and Pfizer Inc. He has received honoraria and research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly and Ortho Dermatologics. Dr Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma. Dr Gelfand is a Deputy Editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 79 - N° 1
P. 69-70 - juillet 2018 Retour au numéro
Article précédent
- The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor–? inhibitors versus phototherapy: An observational cohort study
- Jashin J. Wu, Murali Sundaram, Martin Cloutier, Marjolaine Gauthier-Loiselle, Annie Guérin, Rakesh Singh, Arijit Ganguli
- Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States
- Amit Garg, Morgan Birabaharan, Andrew Strunk
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?